Injectable HIV Treatment: Long-Acting Cabenuva

Injectable HIV treatment means swapping daily pills for provider-given shots. The main option, Cabenuva, combines two drugs, cabotegravir and rilpivirine, and is given as injections every one or two months. It's for people already virally suppressed on a stable regimen, not for starting treatment from scratch CDC, HIV Treatment.

What is Cabenuva, the long-acting injectable HIV treatment?

Cabenuva is an FDA-approved, long-acting form of antiretroviral therapy (ART), the combination of medicines that keeps HIV under control. Instead of taking pills every day, a person gets two injections from a healthcare provider on a set schedule. The point isn't to cure HIV (no treatment does that) but to keep the virus suppressed to an undetectable level, which protects the person's health and prevents transmission to partners.

It's worth being clear about what this article is and isn't about. Cabenuva is treatment for people who already have HIV. That's different from injectable PrEP, cabotegravir sold as Apretude, or twice-yearly lenacapavir, which is prevention for people who don't have HIV. Same idea of a long-acting shot, completely different purpose.

Cabenuva = cabotegravir + rilpivirine

Cabenuva pairs two HIV medicines from different drug classes. Cabotegravir is an integrase inhibitor, which blocks HIV from inserting its genetic material into your cells. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), which jams a different step in the virus's replication machinery. Combining drug classes is how all modern ART works: hitting HIV from more than one angle makes it far harder for the virus to develop resistance StatPearls, HIV.

The reason these two can be given as occasional shots is that they're formulated as long-acting suspensions. After injection, the medication releases slowly from the muscle over weeks, keeping drug levels high enough to suppress the virus between visits. That's the whole trick: one injection does the work that a daily pill used to.

Who qualifies for injectable HIV treatment?

Cabenuva is for people who are already virally suppressed on a stable oral regimen CDC, About HIV. In plain terms, that means your HIV is already undetectable on the pills you've been taking, you've had no treatment failures, and there's no known resistance to either cabotegravir or rilpivirine. It is not a starting therapy, you don't get diagnosed and go straight to the shot.

Everyone with HIV should be on ART and should start as soon as possible after diagnosis, because the goal is to drive the viral load down to undetectable National HIV Curriculum. Most people reach undetectable within about six months of starting treatment. Once you're stable and suppressed there, the conversation about switching to injections can begin. Your clinician will also check that you're not on medicines that interact badly with rilpivirine and that you can reliably make every scheduled visit: because with this regimen, missing an appointment is missing a dose.

The schedule: shots every 1 or 2 months, often after an oral lead-in

A healthcare provider gives Cabenuva as two separate intramuscular injections, usually in the buttocks, at each visit. Depending on the dosing plan, that happens either every month or every two months. There's no pill bottle to carry; the medicine lives in the clinic schedule.

Before the injections start, many people take an oral lead-in: the pill forms of cabotegravir and rilpivirine for a short stretch. This step confirms you tolerate both drugs before they're locked into your body as a long-acting depot you can't simply stop. If a side effect shows up during the oral phase, it's easy to back out; once it's injected, it's there for weeks. After the lead-in, you transition to the shots on your chosen cadence.

How well does it work?

For people who qualify, Cabenuva maintains viral suppression about as well as the daily pills it replaces, that's the bar it had to clear for approval. The clinical payoff is the same one that matters for all HIV treatment: staying undetectable.

And undetectable is a big deal, because of U=U, undetectable equals untransmittable. A person with HIV who takes their medicine as prescribed and stays virally suppressed does not transmit HIV to sex partners. This isn't optimism; it's hard trial data. Across the PARTNER, PARTNER2, and Opposites Attract studies, mixed-status couples had more than 125,000 condomless sex acts and recorded zero linked transmissions while the partner with HIV was undetectable (under 200 copies/mL) PARTNER study. So a working injectable regimen is both your health and your prevention CDC, U=U. The real-world evidence is summarized by aidsmap, and our HIV facts and statistics cover the bigger US picture.

Keeping the virus suppressed is also what protects you over the long haul. Untreated HIV slowly destroys the immune system and can progress to AIDS: defined by a CD4 count under 200 cells/mm³ or an opportunistic infection CDC, How HIV Spreads. Treated early and consistently, the picture is the opposite: a 20-year-old who starts ART before their CD4 drops below 200 now has a life expectancy approaching that of the general population Lancet HIV, life expectancy.

Injectable shots vs daily pills: pros and trade-offs

Neither option is automatically better, it depends on what fits your life. Here's an honest comparison.

The most common downside people actually notice is injection-site reactions: soreness, swelling, or a small firm lump where the shot went in, usually settling on its own over a few days. The bigger consideration is structural: this regimen ties you to a clinic schedule. If transportation, travel, or unpredictable work hours make regular visits hard, daily pills may be the safer choice. If remembering a daily dose is the real struggle, the shot removes that problem entirely.

What if you miss a dose?

Missing a Cabenuva appointment is more serious than missing one pill, because there's no daily backup keeping drug levels up. If you know you'll miss or be late for a scheduled injection, call your clinic before the window closes, don't just wait for the next visit. Providers can bridge the gap with the oral cabotegravir and rilpivirine tablets so your levels don't drop into the danger zone where the virus can rebound and develop resistance. Letting drug levels fall unguarded is exactly how a regimen stops working, so the practical rule is simple: plan ahead and never silently skip a shot.

When to see a clinician

Talk to a provider about injectable treatment if you're already on ART, undetectable, and tired of daily pills, that's the population it was built for. If you haven't been diagnosed but had a risk, the priorities are different. Symptoms can't confirm or rule out HIV. Most people (roughly two-thirds or more) get flu-like symptoms two to four weeks after infection, right when the virus is most contagious, but plenty of people have none at all. Only a test tells you for sure CDC Surveillance, 2023.

If a possible exposure was recent, this is urgent: post-exposure prophylaxis (PEP) can prevent infection but must start within 72 hours, so it's an ER or urgent-care conversation today, not a wait-and-see CDC, PEP. Going forward, PrEP, including the injectable cabotegravir option, prevents HIV in people who don't have it CDC, PrEP. To find out where you stand, start with hiv testing, consider an hiv self-testing at home kit, and check when to test after exposure so you test inside the right window. You can get tested through a clinic or order online, and compare testing providers before you choose.

Keep exploring on EasySTD: whether PrEP is right for you, which STD test you need and HIV/AIDS testing.